EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CovalentInDB 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening

Hongyan Du, Xujun Zhang, Zhenxing Wu, Odin Zhang, Shukai Gu, Mingyang Wang, Feng Zhu iD, Dan Li, Tingjun Hou iD, Peichen Pan iD

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkae946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Hongyan Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China. Hauptthemen laut MEDLINE: Drug Design, Drug Discovery. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rational design of targeted covalent inhibitors (TCIs) has emerged as a powerful strategy in drug discovery, known for its ability to achieve strong binding affinity and prolonged target engagement. However, the development of covalent drugs is often challenged by the need to optimize both covalent warhead and non-covalent interactions, alongside the limitations of existing compound libraries. To address these challenges, we present CovalentInDB 2.0, an updated online database designed to support covalent drug discovery. This updated version includes 8303 inhibitors and 368 targets, supplemented by 3445 newly added cocrystal structures, providing detailed analyses of non-covalent interactions. Furthermore, we have employed an AI-based model to profile the ligandability of 144 864 cysteines across the human proteome. CovalentInDB 2.0 also features the largest covalent virtual screening library with 2 030 192 commercially available compounds and a natural product library with 105 901 molecules, crucial for covalent drug screening and discovery. To enhance the utility of these compounds, we performed structural similarity analysis and drug-likeness predictions. Additionally, a new user data upload feature enables efficient data contribution and continuous updates. CovalentInDB 2.0 is freely accessible at http://cadd.zju.edu.cn/cidb/.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignDrug DiscoveryLigandsHumansDrug Evaluation, PreclinicalCysteineDatabases, ChemicalSmall Molecule LibrariesProteome

Substanzen

LigandsCysteineSmall Molecule LibrariesProteome

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.

ORCID-Profile: Feng Zhu, Tingjun Hou, Peichen Pan

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Du, H., Zhang, X., Wu, Z., Zhang, O., Gu, S., Wang, M., Zhu, F., Li, D., Hou, T., & Pan, P. (2025). CovalentInDB 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae946

Vancouver

Du H, Zhang X, Wu Z, Zhang O, Gu S, Wang M, et al. CovalentInDB 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening. Nucleic Acids Research. 2025. doi:10.1093/nar/gkae946

BibTeX
@article{Du2025,
  author = {Du, Hongyan and Zhang, Xujun and Wu, Zhenxing and Zhang, Odin and Gu, Shukai and Wang, Mingyang and Zhu, Feng and Li, Dan and Hou, Tingjun and Pan, Peichen},
  title = {CovalentInDB 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkae946}
}
Kostenlos starten →